APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health

142 Views21 Dec 2025 08:30

Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got FDA approval for first-line treatment of breast cancer.

What is covered in the Full Insight:

Fosun Pharma’s Green Valley Acquisition
FDA Changes on Real-World Evidence
Daiichi Sankyo’s Enhertu FDA Approval
Takeda’s Positive Psoriasis Study Results
Max Healthcare’s Expansion Plans

Tina Banerjee

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 9-minute read)

Discussions

(Paid Plans Only)

Insight Stream